



## NIH to Evaluate Iclaprim Activity against Listeria

August 19, 2019

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID's <sup>1</sup> suite of preclinical services through JMI Laboratories to evaluate iclaprim against *Listeria monocytogenes*, a Gram-positive bacteria causing food-borne, life-threatening infections. The study, to be funded by NIAID, follows earlier *in vitro* testing in which iclaprim was  $\geq 32$ -fold more potent than standard-of-care ampicillin and demonstrated consistent extracellular as well as intracellular activity against *L. monocytogenes*<sup>2</sup>.

Listeriosis is a rare but serious infection usually caused by eating food, such as cheese and other dairy products, deli meat and produce that has been contaminated with *L. monocytogenes*. An estimated 1,600 people in the U.S. get listeriosis each year, and the infection is most likely to sicken pregnant women and their newborns, adults aged 65 or older, and people with weakened immune systems. The disease can lead to septicaemia or meningitis, and about 260 people in the U.S. die from listeriosis annually. If treatment is required, patients are generally given IV antibiotics – ampicillin alone or in conjunction with another antibiotic.

**David Huang, M.D., Ph.D., Chief Medical Officer of Motif Bio, said:** “*Listeriosis is a potentially life-threatening infection for which more effective treatment options are needed. If the results of this study confirm that iclaprim has potent activity against L. monocytogenes, we believe that iclaprim could be a potentially useful treatment option and would warrant further study.*”

<sup>1</sup> NIAID: National Institute of Allergy and Infectious Diseases.

<sup>2</sup> Huang, D. Letter to the Editor: Extracellular and intracellular activity of iclaprim against *Listeria monocytogenes*. *International Journal of Antimicrobial Agents*, 53 (2019) 106–107.

For further information please contact:

### Motif Bio plc

Graham Lumsden (Chief Executive Officer)

[ir@motifbio.com](mailto:ir@motifbio.com)

### Walbrook PR Ltd. (UK FINANCIAL PR & IR)

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780

[motifbio@walbrookpr.com](mailto:motifbio@walbrookpr.com)

### MC Services AG (EUROPEAN IR)

Raimund Gabriel

+49 (0)89 210 2280

[raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)

### LifeSci Advisors (U.S. IR)

Bob Yedid

+1 (646) 597 6989

[bob@lifesciadvisors.com](mailto:bob@lifesciadvisors.com)

### Note to Editors:

#### About Motif Bio

Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim. Motif Bio is seeking approval of iclaprim from the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment. In February 2019, the Company received a Complete Response Letter (CRL) related to the New Drug Application (NDA) for iclaprim for the treatment of ABSSSI. Additional information regarding the CRL can be found in Motif Bio's Annual Report on Form 20-F filed with the SEC on April 15, 2019. Minutes from a meeting with the FDA to discuss the points raised in the CRL were received in June 2019 and indicated that an additional clinical trial will be required prior to granting marketing approval to address the Agency's continued concerns about potential liver toxicity. The Company was encouraged by the FDA to put forth a proposal for a future study and submitted such a proposal for review in July 2019. Motif Bio has been granted a meeting, scheduled for September 19, 2019, with the Agency to discuss the proposed patient population and study design.

The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of *Staphylococcus aureus* lung infections in patients with cystic fibrosis and is in pre-clinical development for this indication.

Iclaprim received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status for the ABSSSI indication. If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated. Motif is also

building a patent estate to provide additional protection for iclaprim and has two U.S. method of use patents issued that will expire in 2037.

### **Forward-Looking Statements**

This press release contains forward-looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio’s product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio’s product candidates, (iii) Motif Bio’s ability to successfully commercialise its product candidates, (iv) Motif Bio’s ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio’s commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of Motif Bio’s product candidates, (viii) Motif Bio’s ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio’s estimates regarding the potential market opportunity for its product candidates, (x) Motif Bio’s ability to raise additional capital to sustain its operations and pursue its strategy and (xi) the factors discussed in the section entitled “Risk Factors” in Motif Bio’s Annual Report on Form 20-F filed with the SEC on April 15, 2019, which is available on the SEC’s web site, [www.sec.gov](http://www.sec.gov). Additionally, there can be no assurance that Motif Bio will regain compliance with Nasdaq rules or maintain its ADS listing on Nasdaq. Motif Bio undertakes no obligation to update or revise any forward-looking statements.



Source: Motif Bio plc